Evidence map›Paper›PMID 40580480›Full record

ArticleCell reports2025

VISTA immune checkpoint blunts radiotherapy-induced antitumor immune response.

Dhanya K Nambiar, Sainiteesh Maddineni, Jimpi Langthasa, Hongbin Cao, Vignesh Viswanathan, Junyan Liu, Md Tauhidul Islam, Nishant Mehta, Jessica Frank, Alexander Real and 14 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Dhanya K NambiarDepartment of Radiation Oncology, Stanford University School of Medicine, Stanford, CA, USA. Electronic address: dknambiar12@gmail.com.
Sainiteesh MaddineniDepartment of Otolaryngology, Head and Neck Surgery, Stanford University School of Medicine, Stanford, CA, USA.
Jimpi LangthasaDepartment of Radiation Oncology, Stanford University School of Medicine, Stanford, CA, USA.
Hongbin CaoDepartment of Radiation Oncology, Stanford University School of Medicine, Stanford, CA, USA.
Vignesh ViswanathanDepartment of Radiation Oncology, Stanford University School of Medicine, Stanford, CA, USA.
Junyan LiuDepartment of Radiation Oncology, Stanford University School of Medicine, Stanford, CA, USA.
Md Tauhidul IslamDepartment of Radiation Oncology, Stanford University School of Medicine, Stanford, CA, USA.
Nishant MehtaDepartment of Bioengineering, Stanford University Schools of Engineering and Medicine, Stanford, CA, USA.
Jessica FrankDepartment of Bioengineering, Stanford University Schools of Engineering and Medicine, Stanford, CA, USA.
Alexander RealDepartment of Bioengineering, Stanford University Schools of Engineering and Medicine, Stanford, CA, USA.
Tia CheunkarndeeDepartment of Radiation Oncology, Stanford University School of Medicine, Stanford, CA, USA.
Eyiwunmi Eghonghon LaseindeDepartment of Radiation Oncology, Stanford University School of Medicine, Stanford, CA, USA.
Bhushan DharmadhikariHummingbird Bioscience, Singapore, Singapore.
Dipti ThakkarHummingbird Bioscience, Singapore, Singapore.
Jerome D Boyd-KirkupHummingbird Bioscience, Singapore, Singapore.
Andrey FinegershDepartment of Otolaryngology, Head and Neck Surgery, Stanford University School of Medicine, Stanford, CA, USA.
Vasu DiviDepartment of Otolaryngology, Head and Neck Surgery, Stanford University School of Medicine, Stanford, CA, USA.
John B SunwooDepartment of Otolaryngology, Head and Neck Surgery, Stanford University School of Medicine, Stanford, CA, USA.
John AlemanDepartment of Pathology, University of Colorado, Anschutz Medical Campus, Aurora, CO, USA.
Xiao-Jing WangDepartment of Pathology, University of Colorado, Anschutz Medical Campus, Aurora, CO, USA; Department of Pathology and Laboratory Medicine, University of California, Davis, School of Medicine, Davis, CA, USA; VA Northern California Health Care System, Sacramento, CA, USA.
Christina KongDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
Lei XingDepartment of Radiation Oncology, Stanford University School of Medicine, Stanford, CA, USA.
Jennifer R CochranDepartment of Bioengineering, Stanford University Schools of Engineering and Medicine, Stanford, CA, USA.
Quynh-Thu LeDepartment of Radiation Oncology, Stanford University School of Medicine, Stanford, CA, USA. Electronic address: qle@stanford.edu.

Funding

NRG Oncology Network Group Operations Center - GY9 BIQSFP Reports/BudgetsU10CA180868 · NCI · NRG ONCOLOGY FOUNDATION, INC. · PI Quynh-Thu Xuan Le, ROBERT S. MANNEL · 2014 to 2026
$206.8M
Translational Oncology Research Program (Project-005)P30CA124435 · NCI · STANFORD UNIVERSITY · PI MICHAEL KENNEY · 2007 to 2026
$71.4M
Translational Biology CoreP01CA257907 · NCI · STANFORD UNIVERSITY · PI Quynh-Thu Xuan Le · 2022 to 2026
$12.0M
Treating recurrent HNSCC with radiation and dual TGF-Beta/PD-L1.P50CA261605 · NCI · UNIVERSITY OF COLORADO DENVER · PI LUCIA, M. SCOTT · 2021 to 2025
$10.1M
Precision imaging for risk stratification and personalized therapy of oropharyngeal cancerR01DE030894 · NIDCR · STANFORD UNIVERSITY · PI Quynh-Thu Xuan Le, Ruijiang Li · 2022 to 2026
$3.0M
The role of Galectin-1 in shaping the immune suppressive landscape in head and neck cancerR01DE029672 · NIDCR · STANFORD UNIVERSITY · PI LE, QUYNH-THU XUAN · 2021 to 2025
$2.9M
Salivary gland response to Desert hedgehog signaling as an antidote to damage from therapeutic radiationR01DE031724 · NIDCR · STANFORD UNIVERSITY · PI PHILIP A BEACHY · 2022 to 2026
$2.5M
Ultra high throughput sequencer for sustaining and enhancing multi-scale genomic studiesS10OD025212 · OD · STANFORD UNIVERSITY · PI SNYDER, MICHAEL P. · 2018 to 2018
$600k
Computer ClusterS10OD021763 · OD · STANFORD UNIVERSITY · PI JI, HANLEE P · 2016 to 2016
$481k
BLRD VA I01 BX003232BLRD VA IK6 BX005962BLRD VA IK6 BX006039NCI NIH HHS P01 CA257907NCI NIH HHS P30 CA124435NCI NIH HHS P50 CA261605NCI NIH HHS U10 CA180868NIDCR NIH HHS R01 DE029672NIDCR NIH HHS R01 DE030894NIDCR NIH HHS R01 DE031724NIH HHS S10 OD021763NIH HHS S10 OD025212
6 · The paper itself

Abstract

Radiotherapy (RT) is a key treatment for solid neoplasms like head and neck cancer (HNC), but it can also activate and recruit immunosuppressive myeloid cells, causing treatment failure. In this study, we examine the role of V-domain immunoglobulin suppressor of T cell activation (VISTA) on myeloid cells during RT. We discovered high VISTA expression on myeloid cells in the tumor microenvironment (TME) of both murine and human HNC, with RT increasing VISTA

Indexed as

B7 AntigensImmunityMembrane ProteinsAnimalsCell Line, TumorFemaleHumansMiceMice, Inbred C57BLMyeloid CellsTumor MicroenvironmentB7 AntigensMembrane ProteinsVSIR protein, humanVsir protein, mouseantitumor immune responseCP: CancerCP: ImmunologyHNSCCimmune checkpointMDSCradiotherapyVISTA

Identifiers

PMID40580480
PMCPMC12832042

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.